Abstract 175P
Background
Advanced gastric adenocarcinoma with both lymph node and peritoneal metastasis has notoriously poor prognosis. However, molecular mechanism of the metastatic process and potential therapeutic targets remain unknown, hence limiting the development of new therapies.
Methods
We recruited 13 treatment-naïve patients who had gastric adenocarcinoma with concurrent lymph node and peritoneal metastasis. DNA and RNA were extracted from tumor biopsy samples collected from the stomach, lymph node and peritoneum, together with 2 mL of peripheral blood for each patient. Whole exome sequencing (WES) and transcriptome sequencing were performed to generate a comprehensive genomic dataset of our cohort.
Results
Analysis of WES data showed that TP53 and CDH1 were the most frequently mutated genes in both the primary and metastatic tumors. All patients had low tumor mutational burden, but 31% (n=4) showed high level of chromosomal instability (CIN). By constructing tumor phylogenetic trees for each patient, we found evidence supporting two distinct processes of peritoneal dissemination that involved either lymphatic system (n=5) or direct seeding into the peritoneal cavity (n=4). In the RNA sequencing analysis, epithelial-mesenchymal transition (EMT) pathway was found the most significantly altered and segregated the patients into the EMT-high group (n=10) that upregated genes in the EMT pathway, and the non-EMT-high group (n=3).
Conclusions
Multi-omics profiling in this study revealed mutational signature and altered signaling pathways in lymph node and peritoneal metastasis. The results could help identify distinct molecular subtypes among patients, laying foundation for the development of molecular-guided therapeutic strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute, Ho Chi Minh city, Vietna.
Funding
Gene Solutions JSC, Ho Chi Minh city, Vietnam.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract